2016 Innovation Competition (Boston, MA)

NangioTx Inc. - making new blood vessels

NangioTx technology based on an angiogenic peptide (V-10) is capable of regenerating blood vessels in ischemic muscles. This feature makes our patented technology a good candidate to treat conditions associated with Peripheral Artery Disease (PAD) and Peripheral Vascular Disease (PVD), particularly claudication, diabetic foot ulcer, critical limb ischemia, and chronic venous insufficiency. In all these indications the underlying etiology of the disease is lack of blood supply. Based on our existing proof of concept showing V-10's efficacy in regenerating new blood vessels/capillaries, we expect to show in human clinical studies evidence of the following: · decrease in claudication, · higher wound healing in diabetic ulcers, · increased blood flow in ischemia, and · reduction in edema and skin discoloration in venous insufficiency. Patients’ benefits would include decrease in pain, ability to walk more and longer, ability to sense and move the limb better, etc. Above indications are associated with a decrease in blood supply to tissues but not a complete blockade. Vascular Endothelial Growth Factor (VEGF), of which V-10 is a mimic, is biologically active in stimulating new vessel formation even with minimal blood supply. We expect V-10 to be effective in generating new vasculature in the tissues of these PAD/PVD-associated symptoms and be an essential part of an overall therapeutic approach for their resolution.

Vivek A. Kumar, Ph.D. Assistant Professor of Biomedical Engineering New Jersey Institute of Technology University Heights Newark, NJ 07102 (O) 973 596 5577 (C) 678 613 1386 vak@njit.edu